Molecular structure of TRAM-34, CAS Number: 289905-88-0
TRAM-34 (CAS 289905-88-0)
See product citations (10)
Alternate Names:
1-[(2-Chlorophenyl)diphenylmethyl]-1H-pyrazole
Application:
TRAM-34 is an inhibitor of IKCa1 channels and a cell proliferation modulator
CAS Number:
289905-88-0
Purity:
≥98%
Molecular Weight:
344.84
Molecular Formula:
C22H17ClN2
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Product Citations
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
TRAM-34 may act to be an inhibitor of cloned and native IK1 channels in human T lymphocytes. These K+ channels have been implicated in over-proliferation of cells. Inhibition of IK1 channels modulates cell proliferation depending on the concentration of TRAM-34. TRAM-34 may cause a halt in cell growth at the G0/G1 phase.
TRAM-34 (CAS 289905-88-0) References
- Design of a potent and selective inhibitor of the intermediate-conductance Ca2+-activated K+ channel, IKCa1: a potential immunosuppressant. | Wulff, H., et al. 2000. Proc Natl Acad Sci U S A. 97: 8151-6. PMID: 10884437
- K+ channels as targets for specific immunomodulation. | Chandy, KG., et al. 2004. Trends Pharmacol Sci. 25: 280-9. PMID: 15120495
- K+ channel blockers: novel tools to inhibit T cell activation leading to specific immunosuppression. | Panyi, G., et al. 2006. Curr Pharm Des. 12: 2199-220. PMID: 16787250
- Blockage of intermediate-conductance-Ca(2+) -activated K(+) channels inhibits progression of human endometrial cancer. | Wang, ZH., et al. 2007. Oncogene. 26: 5107-14. PMID: 17310992
- TRAM-34 inhibits nonselective cation channels. | Schilling, T. and Eder, C. 2007. Pflugers Arch. 454: 559-63. PMID: 17318643
- TRAM-34, a putatively selective blocker of intermediate-conductance, calcium-activated potassium channels, inhibits cytochrome P450 activity. | Agarwal, JJ., et al. 2013. PLoS One. 8: e63028. PMID: 23667566
- Inhibition of vascular calcification by block of intermediate conductance calcium-activated potassium channels with TRAM-34. | Freise, C. and Querfeld, U. 2014. Pharmacol Res. 85: 6-14. PMID: 24813858
- Ca2+ -activated K+ channel-3.1 blocker TRAM-34 alleviates murine allergic rhinitis. | Lin, H., et al. 2014. Int Immunopharmacol. 23: 642-8. PMID: 25466273
- TRAM-34 attenuates hypoxia induced pulmonary artery smooth muscle cell proliferation. | Guo, SJ., et al. 2015. Eur Rev Med Pharmacol Sci. 19: 3515-21. PMID: 26439051
- The KCa3.1 blocker TRAM-34 inhibits proliferation of fibroblasts in paraquat-induced pulmonary fibrosis. | Xie, H., et al. 2018. Toxicol Lett. 295: 408-415. PMID: 30036685
- Evaluation of a novel combination of TRAM-34 and ascorbic acid for the treatment of corneal fibrosis in vivo. | Fuchs, AA., et al. 2022. PLoS One. 17: e0262046. PMID: 35007294
- Effects of TRAM-34 and minocycline on neuroinflammation caused by diabetic ketoacidosis in a rat model. | Glaser, N., et al. 2022. BMJ Open Diabetes Res Care. 10: PMID: 35584854
- Dextran sodium sulfate potentiates NLRP3 inflammasome activation by modulating the KCa3.1 potassium channel in a mouse model of colitis. | Zeng, B., et al. 2022. Cell Mol Immunol. 19: 925-943. PMID: 35799057
Inhibitor of:
Ik1, KCNN2, SK3, Slo3, SMRT/SMRTe, TAX-4, and TRESK.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
TRAM-34, 5 mg | sc-201005 | 5 mg | $193.00 | |||
TRAM-34, 25 mg | sc-201005A | 25 mg | $607.00 |